Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Provectus Biopharmaceuticals, Inc. (PVCT : OTCBB)
 
 • Company Description   
Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. The company's product portfolio consists of PV-10 Melanoma, PH-10 Psoriasis, PH-10 Atopic Dermatitis, PV-10 Breast Cancer, PV-10 Liver Metastasis and PV-10 Mechanism of Action which are in clinical trials. Provectus Biopharmaceuticals Inc., formerly known as Provectus Pharmaceuticals, Inc., is based in Knoxville, Tennessee.

Number of Employees: 4

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.06 Daily Weekly Monthly
20 Day Moving Average: 215,251 shares
Shares Outstanding: 419.45 (millions)
Market Capitalization: $23.66 (millions)
Beta: 0.14
52 Week High: $0.08
52 Week Low: $0.04
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -6.00% 5.88%
12 Week -17.42% -9.21%
Year To Date 2.55% 25.30%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
10025 INVESTMENT DRIVE SUITE 250
-
KNOXVILLE,TN 37932
USA
ph: 866-594-5999
fax: 866-998-0005
investorrelations@pvct.com http://www.provectusbio.com
 
 • General Corporate Information   
Officers
Heather Raines - Chief Financial Officer
Ed Pershing - Chairman of the Board
Dominic Rodrigues - Vice Chairman of the Board
Bruce Horowitz - Chief Operating Officer
Webster Bailey - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74373P108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/21
Next Expected EPS Date: 05/24/22
Share - Related Items
Shares Outstanding: 419.45
Most Recent Split Date: (:1)
Beta: 0.14
Market Capitalization: $23.66 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/24/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -267.27
12/31/21 - -414.21
09/30/21 - -984.67
Current Ratio
03/31/22 - 0.35
12/31/21 - 0.45
09/30/21 - 0.14
Quick Ratio
03/31/22 - 0.35
12/31/21 - 0.45
09/30/21 - 0.14
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -2,612.40
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -0.01
12/31/21 - -0.01
09/30/21 - -0.01
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©